Advertisement
Canada markets open in 6 hours 12 minutes

  • S&P/TSX

    21,871.96
    +64.59 (+0.30%)
     

  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     

  • DOW

    38,239.98
    +253.58 (+0.67%)
     

  • CAD/USD

    0.7297
    -0.0004 (-0.05%)
     

  • CRUDE OIL

    83.02
    +0.17 (+0.21%)
     

  • Bitcoin CAD

    90,968.56
    +246.42 (+0.27%)
     

  • CMC Crypto 200

    1,399.00
    -15.76 (-1.11%)
     

  • GOLD FUTURES

    2,315.70
    -30.70 (-1.31%)
     

  • RUSSELL 2000

    1,967.47
    +19.82 (+1.02%)
     

  • 10-Yr Bond

    4.6230
    +0.0080 (+0.17%)
     

  • NASDAQ futures

    17,363.75
    +13.75 (+0.08%)
     

  • VOLATILITY

    16.94
    0.00 (0.00%)
     

  • FTSE

    8,063.66
    +39.79 (+0.50%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • CAD/EUR

    0.6848
    -0.0002 (-0.03%)
     

Today’s Research Reports on Eyecarrot Innovations, Antibe Therapeutics, Emblem and Theralase Technologies

ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / April 20, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI has Initiated Coverage Today on:

Eyecarrot Innovations Corp.
https://rdinvesting.com/news/?ticker=EYC.V

Antibe Therapeutics Inc.
https://rdinvesting.com/news/?ticker=ATE.V

Emblem Corp.
https://rdinvesting.com/news/?ticker=EMC.V

Theralase Technologies Inc.
https://rdinvesting.com/news/?ticker=TLT.V

ADVERTISEMENT

Eyecarrot's stock jumped 19.05% Thursday, to close the day at $0.25. The stock recorded a trading volume of 124,000 shares, which was above its three months average volume of 33,580 shares. In the last year, Eyecarrot's shares have traded in a range of 0.10 - 0.25. The share price has gained 150.00% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.18 is greater than its 200-day moving average of $0.16. Shares of Eyecarrot Innovations have gained approximately 47.06 percent year-to-date.

Access RDI’s Eyecarrot Innovations Corp. Research Report at:
https://rdinvesting.com/news/?ticker=EYC.V

On Thursday, shares of Antibe Therapeutics recorded a trading volume of 763,322 shares, which was below the three months average volume of 2,458,525 shares. The stock ended the day 2.08% lower at 0.47. The share price has gained 487.50% from its 52 week low with a 52 week trading range of 0.08 - 0.79. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.40 is greater than its 200-day moving average of $0.22. Shares of Antibe Therapeutics have gained approximately 235.71 percent year-to-date.

Access RDI’s Antibe Therapeutics Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ATE.V

Emblem's stock edged 0.65% higher Thursday, to close the day at $1.56. The stock recorded a trading volume of 411,274 shares, which was below its three months average volume of 801,437 shares. In the last year, Emblem's shares have traded in a range of 1.18 - 26.32. The share price has gained 32.20% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $1.44 is below its 200-day moving average of $1.72. Shares of Emblem have fallen approximately 31.58 percent year-to-date.

Access RDI’s Emblem Corp. Research Report at:
https://rdinvesting.com/news/?ticker=EMC.V

On Thursday, shares of Theralase Technologies recorded a trading volume of 60,975 shares, which was below the three months average volume of 130,474 shares. The stock ended the day 2.27% higher at 0.23. The share price has gained 18.42% from its 52 week low with a 52 week trading range of 0.19 - 0.55. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.23 is below its 200-day moving average of $0.28. Shares of Theralase Technologies have fallen approximately 8 percent year-to-date.

Access RDI’s Theralase Technologies Inc. Research Report at:
https://rdinvesting.com/news/?ticker=TLT.V

Our Actionable Research on Eyecarrot Innovations Corp. (TSXV :EYC.V), Antibe Therapeutics Inc. (TSXV :ATE.V), Emblem Corp. (TSXV :EMC.V) and Theralase Technologies Inc. (TSXV :TLT.V) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com